Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OUtMATCH: Omalizumab as Monotherapy and Adjunct to OIT in Food Allergy
NCT03881696Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in peanut allergy and food allergy (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Participants Who Successfully Consume a Single Dose of >=600 mg of Peanut Protein Without Dose-Limiting Symptoms During the DBPCFC. Started Jul 2019; status: completed.
02
Drugs
omalizumab
03
Conditions
peanut allergyfood allergy
Beyond the preview
Go deeper on NCT03881696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881696.